Notice
Recent Posts
Recent Comments
Link
| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 |
Tags
- structure therapeutics
- Mash
- glp-1 비만
- nash/mash
- lilly
- 제약바이오
- survodutide
- danuglipron
- orforglipron
- 자가면역질환 치료제
- 비만치료제
- GLP-1
- Semaglutide
- 경구용 glp-1
- il-17 inhibitor
- 노보노디스크
- Novo Nordisk
- Pfizer
- gsbr-1290
- VK2735
- GPCR
- VKTX
- Viking Therapeutics
- 바이오스터디
- tirzepatide
- tern-601
- GLP-1 치료제
- CAR-T
- Nash
- glp-1 비만치료제
Archives
- Today
- Total
목록mRNA-4571 (1)
제약바이오 츄롸이츄롸이
RAPT Therapeutics (NASDAQ: RAPT) - 2024 AACR 발표
2024 AACR에서 RAPT Therapeutics 발표 사항: Late-breaking poster presentation details: Title: Phase 2 Study of Oral CCR4 Antagonist FLX475 (tivumecirnon) Plus Pembrolizumab in Subjects with Head and Neck Squamous Cell Carcinoma (HNSCC) Previously Treated with Checkpoint Inhibitor Abstract Number: CT226 Date & Time: Tuesday, April 9, 2024; 9:00 a.m. – 12:30 p.m. PT Session Title: Phase II Clinical Trial..
개별 스터디
2024. 4. 10. 18:16